ES2916449T3 - Inhibidores de DCN1 de molécula pequeña covalentes y métodos terapéuticos de uso de los mismos - Google Patents
Inhibidores de DCN1 de molécula pequeña covalentes y métodos terapéuticos de uso de los mismos Download PDFInfo
- Publication number
- ES2916449T3 ES2916449T3 ES18720910T ES18720910T ES2916449T3 ES 2916449 T3 ES2916449 T3 ES 2916449T3 ES 18720910 T ES18720910 T ES 18720910T ES 18720910 T ES18720910 T ES 18720910T ES 2916449 T3 ES2916449 T3 ES 2916449T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- compound
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483640P | 2017-04-10 | 2017-04-10 | |
| PCT/US2018/026789 WO2018191199A1 (en) | 2017-04-10 | 2018-04-10 | Covalent small molecule dcn1 inhibitors and therapeutic methods using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2916449T3 true ES2916449T3 (es) | 2022-07-01 |
Family
ID=62067873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18720910T Active ES2916449T3 (es) | 2017-04-10 | 2018-04-10 | Inhibidores de DCN1 de molécula pequeña covalentes y métodos terapéuticos de uso de los mismos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10500194B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3609876B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7086171B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110740996B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018251687B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3059256C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2916449T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018191199A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| CA3119781A1 (en) * | 2018-11-20 | 2020-05-28 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| IL323757A (en) | 2019-03-15 | 2025-12-01 | Fulcrum Therapeutics Inc | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| EP4259132A4 (en) * | 2020-12-10 | 2025-01-15 | Adgero Biopharmaceuticals Holdings, Inc. | METHODS OF TREATMENT OF METASTATIC SKIN CANCER |
| CN112830957B (zh) * | 2021-01-07 | 2022-07-22 | 江西师范大学 | 一种制备卡非佐米的方法 |
| WO2023059605A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023059582A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| IL316803A (en) | 2022-06-06 | 2025-01-01 | C4 Therapeutics Inc | Bicyclic glutarimide-modified cervalon-binding agents |
| CN116987062A (zh) * | 2023-08-03 | 2023-11-03 | 中国热带农业科学院分析测试中心 | 一种氨基酸键联槟榔碱衍生物的制备方法 |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| US12435087B2 (en) | 2023-11-03 | 2025-10-07 | Cellarity, Inc. | Modulators of DCN-1 and methods of use thereof |
| US12473285B2 (en) | 2023-11-03 | 2025-11-18 | Cellarity, Inc. | DCN-1 modulating compounds and methods of use thereof |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234264A (en) * | 1989-06-29 | 1993-05-26 | Warner Lambert Co | N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions |
| AU2016324483B2 (en) * | 2015-09-18 | 2021-07-29 | Memorial Sloan Kettering Cancer Center | Methods and compositions of inhibiting DCN1-UBC12 interaction |
-
2018
- 2018-04-10 JP JP2020504290A patent/JP7086171B2/ja active Active
- 2018-04-10 WO PCT/US2018/026789 patent/WO2018191199A1/en not_active Ceased
- 2018-04-10 EP EP18720910.1A patent/EP3609876B1/en active Active
- 2018-04-10 CN CN201880038225.2A patent/CN110740996B/zh active Active
- 2018-04-10 US US15/949,799 patent/US10500194B2/en active Active
- 2018-04-10 AU AU2018251687A patent/AU2018251687B2/en active Active
- 2018-04-10 CA CA3059256A patent/CA3059256C/en active Active
- 2018-04-10 ES ES18720910T patent/ES2916449T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110740996A (zh) | 2020-01-31 |
| AU2018251687B2 (en) | 2021-07-29 |
| AU2018251687A1 (en) | 2019-10-24 |
| CN110740996B (zh) | 2024-01-09 |
| US20180289677A1 (en) | 2018-10-11 |
| WO2018191199A1 (en) | 2018-10-18 |
| JP7086171B2 (ja) | 2022-06-17 |
| JP2020516679A (ja) | 2020-06-11 |
| US10500194B2 (en) | 2019-12-10 |
| CA3059256A1 (en) | 2018-10-18 |
| CA3059256C (en) | 2024-04-16 |
| EP3609876A1 (en) | 2020-02-19 |
| EP3609876B1 (en) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3609876B1 (en) | Covalent small molecule dcn1 inhibitors and therapeutic methods using the same | |
| US12012467B2 (en) | Small molecule DCN1 inhibitors and therapeutic methods using the same | |
| EP2888265B1 (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same | |
| ES2819232T3 (es) | Inhibidores de Bcl-2/Bcl-xL y su uso en el tratamiento de cáncer | |
| CN114341162B (zh) | 作为治疗剂的细胞毒素的肽缀合物 | |
| EP2668180B1 (en) | Bcl-2/bcl-xl inhibitors for use in the treatment of cancer | |
| JP4674231B2 (ja) | ２量体小分子アポトーシス増強剤 | |
| US9233086B2 (en) | Inhibition of WDR5 interaction with its binding partners | |
| CA2901613C (en) | Dual mek/pi3k inhibitors and therapeutic methods using the same | |
| ES2910071T3 (es) | Compuestos de aminopirazina diol como inhibidores de PI3K-Y | |
| AU2012209295A1 (en) | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | |
| WO2010077589A2 (en) | Stat3 inhibitors and therapeutic methods using the same | |
| EP3630099A1 (en) | Bax activators and uses thereof in cancer therapy | |
| WO2013082017A1 (en) | Cyclized peptidomimetic small molecule inhibitors of the wdr5 and mll1 interaction | |
| CN117440813A (zh) | 治疗脑或cns的癌转移的egfr降解剂 | |
| ES2549443T3 (es) | Pirimido[1,2-b]indazoles sustituidos y su uso como moduladores de la ruta de PI3K/AKT | |
| CA3119882A1 (en) | Heterocyclic spiro-compounds as am2 receptor inhibitors | |
| WO2025255442A1 (en) | Trim21-targeted compounds and uses thereof | |
| HK40005133B (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same |